GlaxoSmithKline is looking for opportunities in neurosciences
Collaboration with others in industry, academia, government and non-governmental organisations and healthcare in general is fundamental to GSK's strategic priorities of growing a diversified, global business and delivering more products of value.
Their Worldwide Business Development group is a global team of scientific, transaction, and alliance management experts building diverse collaborations relating to compounds (early stage discovery programs through to marketed products) and technologies. If you prefer to retain the independence to develop alliance compounds through to proof of concept, their Options based collaborative model offers you the flexibility for you to do so. They have an industry leading record in establishing and maintaining collaborations with scientists and organizations in both industry and academia and are experts at building progressive relationships that are strong and mutually beneficial.
Priority areas of science
They are strongly committed to research collaborations with academic groups to advance scientific understanding relevant to their key areas of focus:
- Metabolic pathways
- Infectious diseases
Specific topics of interest currently for academic collaboration are outlined below.
- Translational technologies for neurosciences (e.g. clinical assessments, experimental study methods)
- Increased understanding of the inherent variability and stratification within neuroscience disease populations (including Alzheimer’s and Parkinson’s), and novel outcome measures
- Novel CNS drug delivery technologies
- Imaging of pathophysiology and pathology of CNS disorders, including neurodegeneration
- Novel targets, MOA or translational medicine in neurodegenerative disorders in general (including Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington’s Disease)